Lineage Cell Therapeutics: Not Yet Attractive Stem Cell Company [Seeking Alpha]
Lineage Cell Therapeutics, Inc. (LCTX)
Company Research
Source: Seeking Alpha
The company has treated over 50 patients with no rejections and has seen 5 cases of retinal regeneration on a single administration per patient. Lead asset OpRegen is in a phase 2 trial for dry AMD and has already treated 24 patients, with Genentech investing $50mn and potentially up to $620mn more. Lineage Cell Therapeutics ( LCTX develops cell therapies for degenerative diseases. The company has 5 cell types in active development across its 3 clinical and 2 preclinical programs. The company has already treated over 50 patients with no rejections, and there have been 5 "unprecedented" cases of retinal regeneration on a single administration per patient so far. LCTX works by using Pluripotent Cell Lines (ES or iPS). ES is Embryonic Stem Cells which are harvested from embryos through in vitro fertilization (IVF). They are naturally pluripotent, meaning they can differentiate from all three germ layers (ectoderm, mesoderm, and endoderm) into any of the over 200 types of human cel
Show less
Read more
Impact Snapshot
Event Time:
LCTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LCTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LCTX alerts
High impacting Lineage Cell Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
LCTX
News
- Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development [Yahoo! Finance]Yahoo! Finance
- Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate DevelopmentBusiness Wire
- These 2 ‘Strong Buy' Penny Stocks Could Go Boom, Say Analysts [Yahoo! Finance]Yahoo! Finance
- Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium [Yahoo! Finance]Yahoo! Finance
- Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor SymposiumBusiness Wire
LCTX
Earnings
- 3/7/24 - Beat
LCTX
Analyst Actions
- 2/5/24 - Cantor Fitzgerald